



ASX Release

Sydney, Australia Monday 12 September 2016

Correction to previous ASX Release re Letter of Demand from PrIME and Manukan re A-Bio Debt Repayment

Memphasys Limited (**ASX: MEM**) ("Memphasys") advises that its announcement earlier today regarding receipt of a Letter of Demand incorrectly stated that the letter was issued by lawyers acting on behalf of PrIME Biologics ("PrIME") and Pulau Manukan Ventures Labuan Ltd ("Manukan").

The letter was in fact sent by Manukan on behalf of Manukan and PrIME.

The previous announcement remains correct in all other respects.

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for commercial applications. The Company's patented membrane processes enable the selection of high value substances or contaminants from the fluid in which they are contained by applying an electrical field (electrophoresis) to a sample of the fluid that is contained between our "restriction" membranes and flows through another membrane for separation.

Memphasys Limited
30-32 Richmond Road
Homebush West NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
P +612 8415 7300
F +612 8415 7399

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556